Loading organizations...
§ Private Profile · 313 Pleasant St Ste 4W, Watertown, Massachusetts, 02472, United States
Biotechnology company developing novel enzymatic RNA oligonucleotide synthesis technology to address challenges in RNA therapeutics.
EnPlusOne Biosciences is a Watertown, Massachusetts-based biotechnology company that develops novel enzymatic RNA oligonucleotide synthesis technology to address complex manufacturing challenges in the production of RNA therapeutics. The organization licenses and commercializes a controlled enzymatic platform that was originally developed through collaborative research at Harvard's Wyss Institute and the laboratory of geneticist George Church. To support its ongoing commercialization and drug development efforts, the enterprise secured a worldwide exclusive licensing agreement with Harvard’s Office of Technology Development. In late December 2024, the firm filed an amended SEC Form D to reflect its current operational status, followed by the strategic appointment of Clare Murray as chief executive officer in early 2025 to guide future corporate growth. EnPlusOne Biosciences was founded in 2021 by George Church, Jonathan Rittichier, Dan Ahlstedt, Thomas Wiegand, and Ryan Lee.
EnPlusOne Biosciences has raised $32.0M across 3 funding rounds.
EnPlusOne Biosciences has raised $32.0M in total across 3 funding rounds.
EnPlusOne Biosciences has raised $32.0M in total across 3 funding rounds.
EnPlusOne Biosciences's investors include Breakout Ventures, Northpond Ventures, Andrew Lee.
EnPlusOne Biosciences has raised $32.0M across 3 funding rounds. Most recently, it raised $10.0M Other Equity in February 2025.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Feb 19, 2025 | $10M Venture Round | Breakout Ventures, Northpond Ventures | — | Announced |
| Feb 1, 2025 | $10M Series U | Breakout Ventures, Northpond Ventures, Andrew LEE | — | Announced |
| Sep 1, 2022 | $12M Seed | Northpond Ventures | Breakout Ventures | Announced |
EnPlusOne Biosciences is a biotechnology company developing an enzymatic RNA synthesis platform called ezRNA™ to enable scalable production of RNA therapeutics and vaccines.[1][2][3] It addresses limitations in traditional chemical synthesis by using enzymes for de novo RNA synthesis, single RNA extensions, and diverse nucleotide modifications under aqueous conditions, serving biotech firms and researchers needing efficient, sustainable RNA manufacturing.[1][2] The company, founded in 2022 and based in Watertown, MA, has raised approximately $22M in funding, including a $12M seed round, with early momentum from milestones like synthesizing the antisense strand of the approved siRNA drug Leqvio® and securing an ARPA-H agreement for RNA immunotherapeutics via Wyss Institute collaboration.[1][4]
EnPlusOne Biosciences was founded in 2022 by Daniel Wiegand (Co-Founder & CEO, MSChE), Jonathan Rittichier (Co-Founder & CSO, PhD), and Dan Ahlstedt (Co-Founder & COO, MBA) in Watertown, Massachusetts.[1][3][5] The founders emerged from prestigious programs like the Blavatnik Fellowship in Life Science Entrepreneurship, which provided key resources and mentorship; Ahlstedt previously worked at Sanofi on cGMP manufacturing for enzyme therapies, aligning with the company's RNA focus.[3][5] The idea stemmed from systemic flaws in chemical RNA synthesis, amid surging demand for RNA therapeutics post-COVID, leading to the ezRNA™ platform for enzymatic alternatives.[1][2][3] In 2025, Clare (likely Clare Madden, based on context) joined as CEO, bringing expertise from co-founding Life Edit Therapeutics (ElevateBio), where she drove deals with Moderna and Novo Nordisk, and prior roles at Evotec, SCYNEXIS, and Novartis.[5] Early traction includes seed funding from Northpond Ventures, Breakout Ventures, and Coatue, plus technical proofs like Leqvio® synthesis.[1][4]
EnPlusOne rides the RNA therapeutics boom, fueled by mRNA vaccines' success and demand for siRNA, antisense, and modified RNAs, while shifting to sustainable synthesis amid chemical methods' waste and cost barriers.[1][2] Timing is ideal post-2020s RNA surge, with market forces like multi-billion patient needs (e.g., hypercholesterolemia via Leqvio®) and regulatory pushes for green biotech favoring enzymatic tech.[2][4] It influences the ecosystem by enabling diverse RNA forms efficiently, lowering barriers for developers, and supporting platforms like immunotherapeutics, potentially accelerating therapies from startups to pharma giants.[2][4]
EnPlusOne is poised for expansion with its ezRNA™ platform proving commercial viability, likely pursuing Series A funding, manufacturing scale-up, and partnerships for clinical RNA programs.[1][4][5] Trends like AI-optimized enzymes, mRNA personalization, and global vaccine demands will propel it, especially with CEO Clare's deal-making prowess targeting big pharma integrations.[5] Its influence may evolve from platform enabler to key supplier in a $100B+ RNA market, transforming access to therapeutics much like it promises on its homepage—harnessing enzymes to deliver RNA at scale.[6] This positions EnPlusOne as a cornerstone in biotech's sustainable RNA revolution, building directly on its founding mission.